Darzalex Setback In NHL Raises Stakes For First-Line Myeloma Approval

 
• By Lucie Ellis-Taitt

The pressure is increasing for Genmab and Janssen to report strong first-line multiple myeloma data for recently launched cancer therapy Darzalex, after development of the drug has been suspended for three hematological indications.

Cancer cell
Janssen/Genmab's Darzalex suffers disappointing setback in Phase II NHL studies • Source: Shutterstock

More from Clinical Trials

More from R&D